 Xiu-Ti Hu
Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 13 | 2015 | 43 | 3.970 |
Why?
| | Calcium Channels, L-Type | 7 | 2017 | 58 | 3.600 |
Why?
| | Pyramidal Cells | 11 | 2017 | 40 | 3.420 |
Why?
| | Prefrontal Cortex | 12 | 2017 | 127 | 2.970 |
Why?
| | Nucleus Accumbens | 8 | 2011 | 24 | 2.740 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 5 | 2016 | 16 | 2.380 |
Why?
| | Neurons | 10 | 2017 | 359 | 2.260 |
Why?
| | AIDS Dementia Complex | 4 | 2017 | 37 | 1.780 |
Why?
| | HIV-1 | 7 | 2017 | 404 | 1.740 |
Why?
| | Action Potentials | 8 | 2017 | 112 | 1.730 |
Why?
| | Dopamine Uptake Inhibitors | 6 | 2011 | 16 | 1.580 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 2 | 2016 | 34 | 1.500 |
Why?
| | Calcium | 6 | 2017 | 478 | 1.230 |
Why?
| | Rats | 19 | 2017 | 927 | 1.220 |
Why?
| | Rats, Sprague-Dawley | 16 | 2015 | 473 | 1.070 |
Why?
| | Neuronal Plasticity | 4 | 2009 | 51 | 0.970 |
Why?
| | Animals | 23 | 2017 | 4707 | 0.960 |
Why?
| | Substance Withdrawal Syndrome | 3 | 2010 | 32 | 0.910 |
Why?
| | Sodium Channels | 3 | 2006 | 15 | 0.810 |
Why?
| | Membrane Potentials | 8 | 2016 | 216 | 0.790 |
Why?
| | Receptors, Dopamine D2 | 2 | 2006 | 14 | 0.740 |
Why?
| | Potassium Channels | 2 | 2006 | 42 | 0.730 |
Why?
| | Cerebral Cortex | 2 | 2014 | 164 | 0.710 |
Why?
| | Patch-Clamp Techniques | 9 | 2016 | 135 | 0.690 |
Why?
| | Substance-Related Disorders | 3 | 2017 | 101 | 0.670 |
Why?
| | Calcium Channels | 4 | 2011 | 127 | 0.630 |
Why?
| | Homeostasis | 2 | 2011 | 99 | 0.610 |
Why?
| | Central Nervous System Stimulants | 3 | 2017 | 55 | 0.600 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2011 | 11 | 0.560 |
Why?
| | In Vitro Techniques | 7 | 2011 | 253 | 0.550 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 6 | 2011 | 33 | 0.530 |
Why?
| | Male | 20 | 2017 | 14575 | 0.500 |
Why?
| | Signal Transduction | 6 | 2017 | 512 | 0.500 |
Why?
| | Calcineurin | 2 | 2011 | 11 | 0.500 |
Why?
| | Receptors, Dopamine D1 | 3 | 2011 | 8 | 0.460 |
Why?
| | Calcium Signaling | 2 | 2016 | 165 | 0.450 |
Why?
| | Aging | 1 | 2017 | 1245 | 0.420 |
Why?
| | Inhibitory Postsynaptic Potentials | 1 | 2006 | 2 | 0.400 |
Why?
| | Cyclic AMP | 3 | 2005 | 33 | 0.390 |
Why?
| | Enzyme Inhibitors | 6 | 2011 | 151 | 0.380 |
Why?
| | Phosphoproteins | 1 | 2005 | 34 | 0.360 |
Why?
| | Muscarine | 1 | 2004 | 2 | 0.350 |
Why?
| | beta Catenin | 2 | 2017 | 39 | 0.330 |
Why?
| | Ion Channels | 1 | 2007 | 239 | 0.330 |
Why?
| | Dopamine Agonists | 4 | 2011 | 42 | 0.330 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 149 | 0.330 |
Why?
| | Methamphetamine | 2 | 2017 | 44 | 0.320 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 492 | 0.310 |
Why?
| | Ventral Tegmental Area | 1 | 2002 | 11 | 0.300 |
Why?
| | Amphetamine | 1 | 2002 | 14 | 0.300 |
Why?
| | Disease Models, Animal | 3 | 2017 | 688 | 0.290 |
Why?
| | Electric Stimulation | 4 | 2011 | 86 | 0.270 |
Why?
| | Rats, Transgenic | 2 | 2017 | 18 | 0.260 |
Why?
| | Dopamine Antagonists | 3 | 2011 | 13 | 0.240 |
Why?
| | Drug Interactions | 3 | 2011 | 66 | 0.240 |
Why?
| | Dopamine | 3 | 2007 | 156 | 0.240 |
Why?
| | Analysis of Variance | 2 | 2011 | 357 | 0.230 |
Why?
| | Time Factors | 5 | 2011 | 1614 | 0.230 |
Why?
| | Salicylamides | 2 | 2011 | 2 | 0.220 |
Why?
| | Quinpirole | 2 | 2011 | 3 | 0.220 |
Why?
| | Self Administration | 2 | 2015 | 33 | 0.220 |
Why?
| | Astrocytes | 2 | 2017 | 103 | 0.220 |
Why?
| | Drug Administration Schedule | 3 | 2011 | 244 | 0.220 |
Why?
| | HIV Infections | 2 | 2016 | 788 | 0.200 |
Why?
| | Gene Expression | 1 | 2017 | 245 | 0.190 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 13 | 0.190 |
Why?
| | Mice, Transgenic | 1 | 2016 | 255 | 0.180 |
Why?
| | Drug-Seeking Behavior | 1 | 2015 | 5 | 0.180 |
Why?
| | Cues | 1 | 2015 | 74 | 0.170 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 312 | 0.170 |
Why?
| | Organ Culture Techniques | 1 | 2014 | 37 | 0.170 |
Why?
| | Potassium Channel Blockers | 3 | 2009 | 8 | 0.150 |
Why?
| | Humans | 6 | 2017 | 25163 | 0.150 |
Why?
| | Motor Cortex | 2 | 2009 | 14 | 0.140 |
Why?
| | Street Drugs | 1 | 2011 | 9 | 0.140 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2010 | 9 | 0.130 |
Why?
| | Reward | 2 | 2010 | 25 | 0.130 |
Why?
| | Sodium Channel Blockers | 2 | 2006 | 2 | 0.120 |
Why?
| | Cross-Linking Reagents | 1 | 2009 | 16 | 0.120 |
Why?
| | Protein Transport | 1 | 2009 | 41 | 0.120 |
Why?
| | Synapses | 1 | 2009 | 43 | 0.120 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2005 | 12 | 0.110 |
Why?
| | Calcium Channel Blockers | 2 | 2005 | 37 | 0.110 |
Why?
| | Phosphorylation | 2 | 2005 | 190 | 0.110 |
Why?
| | Receptors, Dopamine | 1 | 2007 | 28 | 0.100 |
Why?
| | Brain | 1 | 2016 | 1170 | 0.100 |
Why?
| | Type C Phospholipases | 1 | 2006 | 11 | 0.100 |
Why?
| | Adaptation, Physiological | 1 | 2007 | 60 | 0.100 |
Why?
| | Synaptic Transmission | 1 | 2006 | 46 | 0.100 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2005 | 2 | 0.090 |
Why?
| | Protein Phosphatase 1 | 1 | 2005 | 4 | 0.090 |
Why?
| | Motor Activity | 1 | 2009 | 360 | 0.090 |
Why?
| | Muscarinic Antagonists | 1 | 2004 | 1 | 0.090 |
Why?
| | Pertussis Toxin | 1 | 2004 | 4 | 0.090 |
Why?
| | Parasympathomimetics | 1 | 2004 | 4 | 0.090 |
Why?
| | Atropine | 1 | 2004 | 4 | 0.090 |
Why?
| | Thionucleotides | 1 | 2004 | 5 | 0.090 |
Why?
| | Egtazic Acid | 1 | 2004 | 13 | 0.090 |
Why?
| | Chelating Agents | 1 | 2004 | 11 | 0.090 |
Why?
| | Blotting, Western | 1 | 2005 | 227 | 0.090 |
Why?
| | Models, Neurological | 1 | 2004 | 32 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 4 | 0.080 |
Why?
| | Ion Channel Gating | 1 | 2006 | 200 | 0.080 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 2 | 0.080 |
Why?
| | Microinjections | 1 | 2002 | 5 | 0.080 |
Why?
| | Animals, Genetically Modified | 1 | 2017 | 14 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2017 | 17 | 0.050 |
Why?
| | Excitatory Amino Acid Antagonists | 2 | 2009 | 19 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 23 | 0.050 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 50 | 0.050 |
Why?
| | Conditioning, Operant | 1 | 2015 | 15 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 203 | 0.050 |
Why?
| | Mice | 1 | 2017 | 1604 | 0.040 |
Why?
| | Indazoles | 1 | 2010 | 3 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2012 | 462 | 0.030 |
Why?
| | Cocaine-Related Disorders | 1 | 2010 | 16 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 213 | 0.030 |
Why?
| | Down-Regulation | 1 | 2011 | 133 | 0.030 |
Why?
| | Cell Line | 1 | 2011 | 341 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2010 | 99 | 0.030 |
Why?
| | Up-Regulation | 1 | 2011 | 185 | 0.030 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2009 | 1 | 0.030 |
Why?
| | Apamin | 1 | 2009 | 2 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2009 | 12 | 0.030 |
Why?
| | Macrolides | 1 | 2009 | 8 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2009 | 22 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 41 | 0.030 |
Why?
| | Comorbidity | 1 | 2011 | 471 | 0.030 |
Why?
| | Biophysics | 1 | 2009 | 45 | 0.030 |
Why?
| | RNA Interference | 1 | 2009 | 42 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2009 | 39 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 67 | 0.030 |
Why?
| | Peptides | 1 | 2009 | 109 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2009 | 181 | 0.030 |
Why?
| | Kynurenic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Cadmium Chloride | 1 | 2005 | 1 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2005 | 7 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 2005 | 4 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2005 | 3 | 0.020 |
Why?
| | Cesium | 1 | 2005 | 13 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2005 | 19 | 0.020 |
Why?
| | Nifedipine | 1 | 2005 | 8 | 0.020 |
Why?
| | Chlorides | 1 | 2005 | 28 | 0.020 |
Why?
| | Barium | 1 | 2004 | 13 | 0.020 |
Why?
| | Evoked Potentials | 1 | 2004 | 17 | 0.020 |
Why?
| | Cell Separation | 1 | 2004 | 44 | 0.020 |
Why?
|
|
Hu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|